CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.
Ontology highlight
ABSTRACT: Although the introduction of tyrosine kinase inhibitors (TKIs) has improved overall survival of patients with chronic myeloid leukemia (CML), about half of the patients eventually relapse after cessation of TKIs. In contrast, the remainder of the patients maintain molecular remission without TKIs, indicating that the patients' immune system could control proliferation of TKI-resistant leukemic stem cells (LSCs). However, the precise mechanism of immunity against CML-LSCs is not fully understood. We have identified a novel immune target, CXorf48, expressed in LSCs of CML patients. Cytotoxic T cells (CTLs) induced by the epitope peptide derived from CXorf48 recognized CD34+CD38- cells obtained from the bone marrow of CML patients. We detected CXorf48-specific CTLs in th
SUBMITTER: Matsushita M
PROVIDER: S-EPMC5709753 | biostudies-literature | 2017 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA